Medium‑Chain Triglyceride–Supplemented Ketogenic Diet in Parkinson’s Disease: A Small Randomized Feasibility Trial and What It Means for Clinical Practice

Medium‑Chain Triglyceride–Supplemented Ketogenic Diet in Parkinson’s Disease: A Small Randomized Feasibility Trial and What It Means for Clinical Practice

A randomized, double‑blind pilot tested an MCT‑supplemented ketogenic diet (MCT‑KD) in 16 people with moderate Parkinson’s disease. The diet was feasible and acceptable, induced nutritional ketosis by day 4, produced metabolic benefits and nonmotor symptom improvement, but did not change a primary mobility endpoint (TUG) over three weeks.

Ketogenic Diet vs Further Antiseizure Medication in Infants with Drug-Resistant Epilepsy: What the KIWE Trial Adds to Clinical Practice

The KIWE randomised trial (Lancet Neurol 2023) found no superiority of a classic ketogenic diet over an additional antiseizure medication for seizure frequency in infants (1–24 months) with drug‑resistant epilepsy; tolerability and safety profiles were similar, supporting the diet as a viable treatment option.
Culturally Adapted Dementia Caregiver Support in Vietnam: New Evidence from the REACH VN Clinical Trial

Culturally Adapted Dementia Caregiver Support in Vietnam: New Evidence from the REACH VN Clinical Trial

A culturally adapted, multicomponent caregiver intervention (REACH VN) reduced psychological distress and stress among Vietnamese dementia caregivers at 3 months, though most benefits were not sustained at 6 months, highlighting both promise and challenges for scalable dementia care support in low-resource settings.